Table 2.

Median survival for Kaplan-Meier analyses of NSCLC brain metastasis patients treated with pembrolizumab with and without IRAEs

Kaplan-Meier Curve	IRAE (months, 95% CI)	No IRAE (months, 95% CI)	p-value
Overall survival	21 (18-undef.)	10 (7–14)	0.004**
Systemic TTF	15 (2–19)	4 (2–5)	<0.001***
Brain TTF	14 (5–29)	5 (4–8)	0.001**
Overall survival: PD-L1 level:<50%	20 (2-undef.)	10 (6–25)	0.744
Overall survival: PD-L1 level:>50%	Undef. (15-undef.)	13 (5–35)	0.011*
Systemic TTF: PD-L1 level:<50%	2 (1-undef.)	4.5 (3–9)	0.918
Systemic TTF: PD-L1 level:>50%	16 (5-undef.)	3 (1–5)	<0.001***
Brain TTF: PD-L1 level:<50%	6 (1-undef.)	6 (4–9)	0.907
Brain TTF: PD-L1 level:>50%	17 (5-undef.)	3 (2–12)	0.005**
Overall survival: No IRAE vs. Low-grade IRAE	21 (15-undef.)	10 (7–14)	0.026*
Overall survival: No IRAE vs. High-grade IRAE	Undef. (2-undef.)	10 (7–14)	0.040*
Systemic TTF: No IRAE vs. Low-grade IRAE	10 (2–16)	4 (2–5)	0.015*
Systemic TTF: No IRAE vs. High-grade IRAE	19 (1-undef.)	4 (2–5)	0.001**
Brain TTF : No IRAE vs. Low-grade IRAE	15 (5–29)	5 (4–8)	0.002**
Brain TFF : No IRAE vs. High-grade IRAE	11 (1-undef.)	5 (4–8)	0.069

CI, confidence interval; IRAE, immune-related adverse events; TTF, time to treatment failure; Undef., undefined

^*p < 0.05

^**p < 0.01

^***p < 0.001